Sinovac eyes 2 billion doses in annual capacity of virus vaccine by June
Sinovac Biotech’s annual production capacity of Covid-19 vaccine can reach 2 billion doses by June, a company spokesman confirmed to Reuters on March 3.
New Search
If you are not happy with the results below please do another search
Search
50 search results for:
Biden says U.S. will have enough Covid-19 vaccine for every adult by May
/in Business, COVID-19 Vaccines, Facilities/Sites/Manufacturing, Joe Biden, Johnson & Johnson, Merck, Partnerships, U.S. government, United StatesThe United States will have enough Covid-19 vaccine for every American adult by the end of May, President Joe Biden said on March 2 after Merck & Co. agreed to make rival Johnson & Johnson’s inoculation.
Merck to Help Produce Johnson & Johnson’s Covid-19 Vaccine
/in Biomedical Advanced Research and Development Authority (BARDA), Business, COVID-19 Vaccinations, Department of Health and Human Services (HHS), Johnson & Johnson, Manufacturing, Merck, SARS-CoV-2 virusMerck entered into multiple agreements to support efforts to expand manufacturing capacity and supply of SARS-CoV-2/Covid-19 medicines and vaccines.
Agilent Adds Liquid Biopsy Assay
/in Acquisitions, Assays, Breakthrough Device Designation, Business, Diagnostic Tools, Liquid Biopsies, Precision Oncology, Testing, TissueAgilent Technologies, expanding on the company’s precision oncology testing, is acquiring Resolution Bioscience.
FDA Accepts NDA for Oyster Point’s Dry Eye Therapy
/in Business, Clinical Data, Clinical Trials, Dry Eye Disease, FDA, Immunosuppressants, Nasal Sprays, New Drug Applications, R&D, Secondary Endpoints, StocksOyster Point’s New Drug Application (NDA) for the dry eye disease therapy OC-01 was accepted for FDA regulatory review on the back of positive Phase III data.
U.S. trial of Covid-19 blood plasma halted after no benefit found
/in Blood Plasma, Clinical Trials, Convalescent Plasma, COVID-19 Plasma, National Institutes of Health, R&D, Symptoms: Coronavirus Disease 2019 (COVID-19)The U.S. National Institutes of Health (NIH) halted a trial of convalescent blood plasma in the treatment of patients with mild-to-moderate Covid-19 symptoms as it was unlikely to benefit this group.
RED HAVAS EXPANDS GLOBAL HEALTH OFFERING WITH LAUNCH OF RED HAVAS HEALTH
/in Healthcare Communications Agencies, Healthcare Communications Networks, Launches, Marketing & Advertising, Public RelationsRed Havas announced on March 2 the launch of Red Havas Health, a global micro-network focused on health, in response to increasing demand from clients globally
FDA Advisory Panel Meeting for Anemia Drug
/in Advisory Panels, Anemia, AstraZeneca, Business, Cardiovascular and Renal Drugs Advisory Committee, Chronic Kidney Disease, Clinical Trials, FDA, Japanese Ministry of Health, New Drug Applications, Partnership, R&DThe U.S. Food and Drug Administration decided to put together an advisory committee meeting of outside experts to review a New Drug Application (NDA) for FibroGen and partner AstraZeneca’s investigational anemia therapy roxadustat.
Novavax: Covid-19 Vaccine U.S. EUA Possible by May
/in Business, Clinical Trials, COVID-19 Vaccinations, Emergency Use Authorization (EUA), FDA, Interim Data, Novavax, Partnership, Quarterly results, R&D, United StatesNovavax Chief Executive Officer Stanley Erck believes the U.S. Food and Drug Administration could grant Emergency Use Authorization (EUA) for the company’s Covid-19 vaccine by May.
Biden takes steps to help Merck boost Johnson & Johnson Covid-19 vaccine supply
/in Business, Collaborations, Defense Production Act, Facilities/Sites/Manufacturing, Janssen COVID-19 Vaccine (J&J), Joe Biden, Johnson & Johnson, Manufacturing, Manufacturing Plants, Merck, PartnershipsMerck & Co. will help make rival Johnson & Johnson’s Covid-19 vaccine in order to boost the slower-than-promised production of the one-dose shot, U.S. President Joe Biden said on March 2.